案例报告:卡格卢米酸在新生儿中加速氨清除,该新生儿患有甲基马龙酸血症
Qianli Ma1, Yunfeng Luo2, Xu Zhang3
1Department of Clinical Laboratory, Qianxi People's Hospital, Qianxi, Guizhou, China.
Frontiers in pediatrics
|December 17, 2025
概括
卡格卢米酸有效地降低了新生儿的高氨水平,该新生儿患有甲基马龙酸血症 (MMA). 这种治疗对治疗新生儿高氨血症和预防大脑损伤有希望.
科学领域:
- 生物化学 生物化学
- 儿科医学 儿科医学
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 高氨血是新生儿的危险疾病,通常与尿素循环障碍有关.
- 卡格酸是一种N-乙谷氨酸类比物,增强尿素循环活性,用于氨酸排毒.
- 关于卡格卢米酸在新生儿高血的疗效的数据有限,特别是在MMA等新生代谢错误的继发性中.
研究的目的:
- 报告新生儿高氨血病的病例,该病例是二次的甲基马龙酸血病 (MMA).
- 在此背景下,评估卡格卢米酸在治疗急性和长期高氨血的有效性.
- 评估卡格卢米酸对神经发育和生长的影响.
主要方法:
- 一名患有MMA和高氨血症的10天大的女婴被用卡格卢米酸治疗.
- 急性管理涉及高剂量的卡格卢米酸 (200毫克/公斤/天).
- 长期随访包括低剂量维持疗法 (50毫克/公斤/天) 一年,监测氨水平,神经发育和生长.
主要成果:
- 卡格卢米酸的使用导致血氨水平在2天内迅速下降.
- 在维持治疗1年期间,氨水平保持稳定,在可接受的范围内.
- 婴儿在整个随访期间表现出正常的神经发育和生长.
结论:
- 卡格卢米酸是一种潜在的有价值的治疗剂,用于MMA治疗新生儿急性和慢性高氨血症的治疗.
- 早期和持续使用卡格卢米酸的治疗可以预防严重的神经并发症.
- 这一案例凸显了卡格卢米酸在管理复杂的新生儿代谢紧急情况方面的实用性.
相关概念视频
01:23Urea Cycle
The urea cycle describes how liver cells convert ammonia to urea. Ammonia is a toxic waste product of protein catabolism. Land animals must convert ammonia into the less toxic urea which can be safely eliminated by the kidneys through urine. Marine animals excrete ammonia directly, and the surrounding water dilutes the ammonia to safe levels.
01:35Loss of Carboxy Group as CO2: Decarboxylation of Malonic Acid Derivatives
Just like β-keto acids—which upon thermal decarboxylation form ketones—β-dicarboxylic acids undergo decarboxylation to generate monocarboxylic acids with the liberation of carbon dioxide.
01:20Inborn Errors of Metabolism
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:29Hepatic Encephalopathy
DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...